Bills would ban 'authorized generics'

Legislation to prohibit companies from marketing an authorized generic version of a Rx drug until after expiration or forfeiture of any 180-day marketing exclusivity associated with an ANDA for a generic version of the drug has been introduced in the House and Senate.
The Fair Prescription Drug Competition Act was introduced by Sen. Jay Rockefeller (D-WV) with five Democrat co-sponsors. The substantively identical House version was introduced by Rep. Jo Ann Anderson (R-MO).
Rockefeller is quoted as saying that the Waxman-Hatch Act 180-day marketing exclusivity incentive to launch a patent challenge “is being widely undermined by authorized generics (which are) becoming even more prevalent as patents on some of the best-selling brand name pharmaceuticals expire.”
He says passage of his bill would “revitalize and protect the true intent of the 180-day marketing exclusivity period created in the Waxman-Hatch Act.”
In 2004, FDA denied two citizen petitions challenging the marketing of authorized generics. The agency determined that use of authorized generics during a period of marketing exclusivity was a long-standing pro-competitive practice that is permissible under the Federal Food, Drug, and Cosmetic Act. The petition decisions were challenged in court and FDA was upheld.
A 2009 FTC report found that drug prices are lower when authorized generics are marketed against a single generic drug than when they are not.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions